Back to results
US 2024/0192224 A1Published application
Neutralizing antibody assays and compositions
OwnerGe CHEN, Hong LIU +1inventors
InventorsGe CHEN, Hong LIU, Shahrokh SHABAHANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to compositions and methods for assaying antibodies. More specifically, the disclosure relates to assays that detect antibodies that have neutralizing activity against SARS-CoV-2.
Claims21
1-82. (canceled)
A method of detecting SARS-CoV-2 neutralizing antibodies, the method comprising:
- a) combining:
- i) at least two types of identifiably labelled microparticles conjugated to at least two different SARS-CoV-2 proteins or a fragment thereof, at least one of which comprises a SARS-CoV-2 S protein or fragment thereof, with
- ii) a detectably labelled SARS-CoV-2 S protein receptor or a fragment thereof, and
- ii) a test sample;
- b) detecting the identifiable labels and the detectable label both associated with the microparticles to generate detection data;
- and
- c) combining or measuring the detection data to generate a test sample property relating to a presence or absence of or amount of SARS-CoV-2 neutralizing antibodies in the test sample.
4 more elements
A method of detecting SARS-CoV-2 neutralizing antibodies, the method comprising:
- a) one of
- i) combining:
- A) at least one identifiably labelled microparticle conjugated to a SARS-CoV-2 S protein or a fragment thereof with
- B) a detectably labelled SARS-CoV-2 S protein receptor or a fragment thereof, and
- C) a test sample, or
- ii) combining:
- A) identifiably labelled microparticles conjugated to a SARS-CoV-2 S protein receptor or a fragment thereof with
- B) a detectably labelled SARS-CoV-2 S protein or a fragment thereof, and
- C) a test sample;
- b) detecting an identifiable label and a detectable label, both associated with microparticles, to generate detection data;
- and
- c) combining or measuring the detection data to generate a test sample property relating to the presence or absence of or amount of SARS-CoV-2 neutralizing antibodies in the test sample.
9 more elements
A composition comprising:
- a) a mixture of at least two types of identifiable microparticles:
- i) a first type conjugated to a first SARS-CoV-2 S protein or fragment thereof, and
- ii) a second type conjugated to a second fragment of SARS-CoV-2 S protein, which is different from the first fragment.
Dependencies are inferred from the claim text.